Clinicians encouraged to consider tocilizumab or sarilumab in treatment of hospitalised COVID-19 patients
The rheumatoid arthritis drugs, tocilizumab and sarilumab, should be considered in the treatment of COVID-19 patients admitted to intensive care, according to updated NHS guidance.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
More News: Actemra | Arthritis | COVID-19 | Drugs & Pharmacology | Intensive Care | Rheumatoid Arthritis | Rheumatology